Interpretation 410
Tier 1|
|
|
Primary Sites
Tumor Types
Interpretation
The V654A c-KIT kinase domain mutation has been associated with imatinib-resistant GIST relapse, representing about 47% of all GIST secondary mutations. GIST harboring KIT V654A is still sensitive to Sunitinib and Sorafenib. drug: Nilotinib, Sunitinib
Citations
- Roberts KG, et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007;6(3):1159-66
- Wang L, et al. Genomic sequencing for cancer diagnosis and therapy. Annu Rev Med 2014;65():33-48
- Demetri GD, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329-38
- George S, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45(11):1959-68
- Reichardt P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer 2015;121(9):1405-13
- Reichardt P, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23(7):1680-7
- Montemurro M, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009;45(13):2293-7
- Sawaki A, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117(20):4633-41
Last updated: 2018-04-18 14:21:29 UTC